PolarityTE Expands Contract Services Business with Addition of Jon Burrows
SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the appointment of Jon Burrows, PhD as President of Contract Services and Senior Vice President of Corporate Development. Dr. Burrows will oversee the market expansion of the Company's contract research organization (CRO) services, including that of its wholly-owned subsidiary, IBEX Preclinical Research, as well as corporate development efforts at large.
"Jon brings a wealth of knowledge that will help bring our contract services business forward. His experience in everything from preclinical and clinical research leadership to precision medicine and commercialization will guide his work at PolarityTE," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
Dr. Burrows commented, "PolarityTE has the ability to change the practice of regenerative medicine and tissue engineering as we know it. The opportunity to join this exciting and quickly growing company was one that I could not ignore. I look forward to joining the impressive team assembled thus far and helping the business realize its full potential."
Dr. Burrows has over 20 years of experience encompassing academic medical research in numerous pharmaceutical and biotechnology industry roles. He is a successful executive, entrepreneurial scientist and motivating business leader with a broad base of experience across translational medicine, drug development and precision medicine. Prior to accepting his position at PolarityTE, Dr. Burrows helped lead an early development stage consulting and clinical advisory group, which he co-founded in 2015. Notably, from 2012-2015, Dr. Burrows was President and CEO of OncoPlex Diagnostics. During his tenure as CEO, Dr. Burrows successfully rebranded the company and used his accumulated experience and network in oncology drug development, clinical trials and molecular diagnostics to successfully transform the early stage research tools company into a clinical diagnostics company with marketed products and significant sales traction. As a result of Dr. Burrows' corporate development efforts and ability to refocus the company, OncoPlex successfully completed a high-value acquisition with NantOmics in 2015. Prior to his success with OncoPlex, Dr. Burrows held multiple positions leading both preclinical, translational medicine and clinical research programs for companies like Sugen/Pharmacia (acquired by Pfizer), Rigel Pharmaceuticals and Chiron (now Novartis Institute for Biomedical Research). In particular, he also held significant leadership and business development roles in Translational Diagnostics at Ventana Medical Systems, an innovative company that manufactured instruments and reagents for automated tissue processing, slide staining and digital pathology in cancer diagnostics, and then Roche immediately following Roche's acquisition of Ventana in 2008.
Dr. Burrows originally trained as an industrial chemist at Leeds University in England and ultimately went on to receive both a Master's in physical chemistry and a PhD in cell and molecular biology from the University of Nevada-Reno. He completed postdoctoral studies at Washington University Children's Hospital before becoming the Alpha-1 Foundation Young Investigator for Clinical Research at Washington University School of Medicine in St Louis. In 2001 he joined industry, building a career in scientific leadership, business development and executive management at multiple major biomedical entities.
About PolarityTE
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE® platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and IBEX are trademarks or registered trademarks of PolarityTE, Inc.
CONTACTS
Investors:
Rich Haerle
VP, Investor Relations
PolarityTE, Inc.
[email protected]
(385) 831-5284
Hans Vitzthum
LifeSci Advisors, LLC
[email protected]
(617) 535-7743
Media:
Jenna Mathis
PolarityTE, Inc.
[email protected]
(610) 751-3985
SOURCE PolarityTE, Inc.
Share this article